ArticleWorld journal of surgical oncology2025
Long non-coding RNAs PCAT-1 and FENDRR: diagnostic and prognostic potential in papillary thyroid carcinoma.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThyroid cancer is the most prevalent endocrine cancer worldwide. Certain histological subtypes of papillary thyroid carcinoma (PTC) exhibit aggressive behavior, with poor clinical outcomes. Long non-coding RNAs (lncRNAs) have emerged as critical regulators of various biological processes, making them promising candidates for cancer biomarkers. PURPOSE: This study aimed to investigate the roles of lncRNAs, specifically prostate cancer-associated transcript 1 (PCAT-1) and Fetal-lethal non-coding developmental regulatory RNA (FENDRR), in the pathogenesis of thyroid carcinoma. Additionally, we evaluated their potential as diagnostic and prognostic markers in PTC.
methodsForty fresh thyroid cancer samples and 36 control goiter tissue samples were analyzed for gene expression levels of PCAT-1 and FENDRR via quantitative real-time polymerase chain reaction (PCR), and Associations with clinicopathological characteristics were analyzed. Receiver operating characteristic (ROC) curves were used to evaluate diagnostic accuracy, and the Kaplan-Meier technique was used to analyze survival. A Cox proportional-hazards regression model was used to assess the effects of several risk variables on survival.
resultsCompared with controls, PTC patients predented significantly increased PCAT-1 expression and decreased FENDRR expression, with high diagnostic accuracy according to ROC curve analysis. Patients with lower FENDRR expression had shorter recurrence-free survival, according to Kaplan-Meier analysis. Low FENDRR gene expression, a tumor size greater than 2 cm, invasion into the capsule, and other lobe malignancies remained significant independent prognostic factors for PTC recurrence according to Cox proportional hazards regression analysis.
conclusionThis study is the first to investigate the expression patterns of PCAT-1 and FENDRR in thyroid cancer. These results indicate that both lncRNAs could be used as diagnostic biomarkers to differentiate PTC from benign thyroid tumors. Furthermore, decreased expression of FENDRR might be used as an independent prognostic factor for predicting PTC recurrence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.